SECTM1 and cancer: In conclusion, our current study systemically analyzes the predictive value of SECTM1 for the responses to immunotherapy and its immunological correlations and identifies SECTM1 as a promising biomarker of benefit to immunotherapy in multiple cancer types in more than ten public and in-house cohorts.